Harvey D. Preisler

Harvey D. Preisler's AcademicInfluence.com Rankings

Harvey D. Preisler

Philosophy

#8347

World Rank

#11705

Historical Rank

Logic

#5380

World Rank

#6774

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Harvey D. Preisler's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Harvey D. Preisler Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Harvey D. Preisler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. (1981) (480)
Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. (1987) (309)
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. (1973) (284)
An autopsy study of 1206 acute and chronic leukemias (1958 to 1982) (1987) (249)
Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation (1976) (220)
Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy. (1979) (212)
A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. (1982) (200)
Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. (2002) (190)
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia (1990) (187)
A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. (1991) (168)
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. (1979) (160)
Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis (1995) (156)
Acute myelogenous leukemia with leukemia cutis. Eighteen cases seen between 1969 and 1986 (1989) (154)
Failure of remission induction in acute myelocytic leukemia. (1978) (153)
c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. (1992) (137)
Expression of the multidrug resistance gene in myeloid leukemias. (1990) (115)
Prediction of response to chemotherapy in acute myelocytic leukemia. (1980) (111)
Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. (1987) (106)
Hemoglobin synthesis in murine virus‐induced leukemic cells in vitro. III. Effects of 5‐bromo‐2′‐deoxyuridine, dimethylformamide and dimethylsulfoxide (1973) (104)
Hemoglobin biosynthesis in murine virus-induced leukemic cells in vitro: structure and amounts of globin chains produced. (1972) (103)
Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. (1990) (101)
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. (1987) (93)
Gastrointestinal “sterilization” in the treatment of patients with acute leukemia (1970) (85)
Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. (2000) (84)
Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer. (1998) (76)
Serologic diagnosis of disseminated candidiasis in patients with acute leukemia. (1968) (75)
Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of Friend leukemic cell differentiation. (1976) (71)
The frequency of long‐term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow‐up time of 6 years (1989) (70)
Acute myelogenous leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy (1977) (69)
A paradigm shift in myelodysplastic syndromes. (1996) (69)
Studies on the control of differentiation of murine virus-induced erythroleukemic cells. (1974) (69)
Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. (1997) (68)
Double labeling and in vitro versus in vivo incorporation of bromodeoxyuridine in patients with acute nonlymphocytic leukemia. (1985) (68)
Rapid enumeration of S-phase cells by means of monoclonal antibodies. (1984) (68)
Two in situ labeling techniques reveal different patterns of DNA fragmentation during spontaneous apoptosis in vivo and induced apoptosis in vitro. (1995) (67)
Differentiation of erythroleukemia cells in vitro: properties of chemical inducers. (1975) (58)
Anti-Candida antibodies in patients with acute leukemia. A prospective study. (1971) (55)
The treatment of acute myelocytic leukemia in patients 30 years of age and younger (1982) (52)
Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside (1984) (52)
Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. (1985) (50)
Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. (2002) (49)
Cryoprotective agents as inducers of erythroleukemic cell differentiation in vitro. (1976) (48)
Chromosomes and causation of human cancer and leukemia. LIV. Near-tetraploidy in acute leukemia. (1985) (48)
The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. (1992) (48)
Enhanced expression of the granulocyte-macrophage colony stimulating factor gene in acute myelocytic leukemia cells following in vitro blast cell enrichment. (1988) (47)
High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study (1986) (45)
Remission induction in acute nonlymphocytic leukemia: comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin. (1979) (44)
Differentiation of erythroleukemic cells in vitro: Irreversible induction by dimethyl sulfoxide (DMSO) (1975) (43)
The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. (1996) (43)
Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements (1986) (41)
Comparison of tritiated thymidine labeling and suicide indices in acute nonlymphocytic leukemia. (1978) (40)
Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy. (1983) (39)
The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. (1999) (35)
Effect of interferon-α on CD20 antigen expression of B-cell chronic lymphocytic leukemia (2000) (35)
Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment. (1994) (35)
AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA IN REMISSION (1987) (34)
Comparison between agar and methylcellulose cultures of human leukemic cells. (1981) (33)
Regulators of Proliferation and Apoptosis in Carcinoma of the Larynx (1998) (33)
Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. (1987) (32)
Effects of an IL-1 receptor antagonist on acute myeloid leukemia cells. (1992) (32)
Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase. (1997) (32)
Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia. (1977) (32)
Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. (1992) (31)
Polyribosome Profiles and Polyribosome-Associated RNA of Friend Leukaemia Cells Following DMSO-induced Differentiation (1973) (31)
Assessment of c-myc expression in individual leukemic cells. (1988) (31)
The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia (1983) (31)
SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. (2000) (30)
Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia (2004) (29)
Telomerase Activity In Preleukemia And Acute Myelogenous Leukemia (2000) (28)
Proliferation of epithelia of noninvolved mucosa in patients with head and neck cancer (1996) (28)
Mutation of p53 in Squamous Cell Cancer of the Head and Neck: Relationship to Tumor Cell Proliferation (1997) (28)
High-dose cytosine arabinoside: clinical response to therapy in acute leukemia. (1982) (27)
Erythropoietin responsiveness of differentiating Friend leukaemia cells (1974) (27)
Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C). (1985) (27)
Relationship of the growth of leukemic cells in vitro to the outcome of therapy for acute nonlymphocytic leukemia. (1984) (27)
Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study (1989) (27)
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation. (1977) (26)
Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment. (1982) (26)
Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study (1993) (26)
Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients. (1992) (26)
Transposition of breakpoint cluster region (3' bcr) in CML cells with variant Philadelphia translocations. (1987) (25)
Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia intergroup report. (1985) (24)
Double labeling of S-phase murine cells with bromodeoxyuridine and a second DNA-specific probe. (1985) (24)
Cell kinetics of head and neck cancers. (1995) (24)
Utility and sensitivity of anti BrdU antibodies in assessing S‐phase cells compared to autoradiography (1985) (22)
Macrophage differentiation of human precursor B-cell line by phorbol ester and colony-stimulating factor. (1982) (22)
Involvement of bands 9q21-q22 in five cases of acute nonlymphocytic leukemia. (1989) (21)
Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues. (1997) (21)
Immunohistochemical detection of c-myc oncoprotein in paraffin embedded tissues. (1990) (21)
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure (1991) (21)
Enzymatic programming of apoptotic cell death. (1996) (21)
Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. (2000) (21)
Immunoperoxidase detection of myeloid antigens in glycolmethacrylate-embedded human bone marrow. (1987) (21)
A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr. (1987) (20)
Evaluation of c-myc proto-oncogene in primary human breast carcinomas. (1991) (20)
Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia (1991) (20)
Cytokine gene activity in AML cells in vivo in patients. (1998) (19)
The ABL/BCR fusion gene on chromosome 9 in Ph-negative chronic myelogenous leukemia: a case for vigilance in fluorescence in situ hybridization interpretation. (1998) (18)
Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamenthasone Produces Encouraging Results in Myelodysplastic Syndromes (1998) (18)
Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. (1986) (18)
A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer. (1998) (18)
Assessment of the drug sensitivity of acute nonlymphocytic leukaemia using the in vitro clonogenic assay (1984) (18)
In Vivo Effects of IL-4, IL-10, and Amifostine on Cytokine Production in Patients with Acute Myelogenous Leukemia (2001) (17)
cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma. (1979) (17)
Treatment of myeloid blastic crisis of chronic myelogenous leukemia. (1984) (17)
The effects of 13-cis retinoic acid and interferon-alpha in chronic myelogenous leukemia cells in vivo in patients. (1997) (17)
Differing patterns of proto-oncogene expression in immature and mature myeloid cells. (1987) (16)
The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study (1992) (16)
A hypothesis regarding the development of acute myeloid leukemia from preleukemic disorders. The role of protooncogenes. (1988) (16)
Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia [letter] (1991) (16)
Treatment failure in AML. (1982) (16)
Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer. (1978) (15)
An Integrated Approach to the Study and Treatment of Acute Myelocytic Leukemia (1982) (15)
Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1 (2000) (15)
Loss of clonogenicity in agar by differentiating erythroleukemic cells. (1975) (15)
Analysis of cell cycle characteristics and course of the disease in ANLL (1987) (14)
Effect of cytosine arabinoside and 1,3-bis(2-chloroethyl)-1-nitrosourea on hematopoietic precursors in the mouse. (1971) (14)
Erythroid colony formation in vitro by dimethylsulfoxide-treated erythroleukemic cells. (1974) (14)
Expression of hematopoietic progenitor cell associated antigen CD34 in chronic myeloid leukemia. (1991) (14)
Clones of Friend leukemia cells: differences in karyotypes and responsiveness to inducers of differentiation. (1976) (14)
Proto-oncogene transcript levels and acute nonlymphocytic leukemia. (1987) (14)
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy. (1996) (13)
Phenylbutazone-induced myelodysplastic syndrome with Philadelphia translocation. (1987) (13)
In vitro busulfan sensitivity of granulocyte-macrophage and erythroid progenitor cells in patients with chronic myelogenous leukemia. (1983) (13)
Uptake of adriamycin by human leukemic cells as measured by flow cytometry (1984) (13)
Differences between labeling index and DNA histograms in assessing S-phase cells from a homogeneous group of chronic phase CML patients. (1985) (12)
Poor prognosis acute myelogenous leukemia. (1993) (12)
Point mutations in both transforming and non-transforming codons of the N-ras proto-oncogene of Ph+ leukemias. (1989) (12)
Alteration of binding of the supravital dye Hoechst 33342 to human leukemic cells by adriamycin. (1978) (12)
Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy. (1981) (12)
Cytokines, molecular biological abnormalities, and acute myelogenous leukemia. (1997) (12)
Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure. (1983) (12)
Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure (1983) (12)
Effects of prior therapy on plasma levels of adriamycin during subsequent therapy. (1981) (12)
Preparation of Autologous Leukemia and Lymphoma Vaccines Expressing α-Gal Epitopes (2001) (12)
c-myc detection in bone marrow biopsies. (1991) (11)
Alcian blue method for attaching glycol methacrylate bone marrow sections to glass slides. (1986) (11)
A study of antibiotic therapy in fever of unknown origin in neutropenic cancer patients. (1977) (11)
Ph1-positive acute leukemia. (1984) (11)
High-dose cytosine arabinoside therapy in acute non-lymphocytic leukemia. (1984) (11)
Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia (1993) (11)
In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias. (1985) (11)
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia (1993) (11)
Protooncogene expression in subpopulations of cells from leukemia patients. (1992) (11)
Effect of suppression of erythropoiesis on hematopoietic stem cells in the mouse (1972) (11)
Treatment of patients with acute nonlymphocytic leukemia in relapse: A leukemia intergroup study (1985) (11)
Comparison of agar and methylcellulose culture methods for human erythroid colony formation. (1982) (11)
Studies on erythroid differentiation of Friend virus-induced murine leukemic cells. (1973) (11)
The treatment of acute non-lymphocytic leukemia. (1987) (11)
An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system. (1993) (10)
Autologous bone marrow transplantation for acute leukemia in remission. (1987) (10)
An acquired Robertsonian translocation dic(14;14)(p11;p11) in a patient with a myelodysplastic syndrome following treatment of multiple myeloma. (1988) (10)
A Comparison of Two Methods for Determining the Sensitivity of Human Myeloid Colony‐forming Units to Cytosine Arabinoside (1981) (10)
A permanent method of detecting SCE by immunofluorescence using monoclonal anti-BrdU antibodies. (1985) (10)
A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography (2004) (10)
Differing patterns of human protooncogene expression in peripheral blood and bone marrow acute leukemia cells. (1987) (10)
Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML. (2001) (10)
Breakpoint cluster region rearrangements in chronic myelogenous leukemia with a masked Philadelphia chromosome. (1987) (10)
Protected environment units in the treatment of acute leukemia. (1975) (10)
Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy (1987) (9)
Studies of the proliferation and differentiation of immature myeloid cells in vitro. II. Acute myelogenous leukemia (1989) (9)
Granulocyte differentiation by Friend leukemia cells. (1975) (9)
Four cases with complex Philadelphia translocations, including one with appearance de novo of a "masked" Ph. (1987) (9)
Clonogenic potential of myeloid leukaemia cells in vitro is restricted to leukaemia cells expressing the CD34 antigen. (1993) (9)
Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration. (1976) (9)
Prevention of infection and bleeding in leukemic patients receiving intensive remission maintenance therapy. (1981) (9)
CD34-positive cell selection by immunomagnetic beads and chymopapain. (1992) (8)
Effects of S-phase-specific agents on granulocyte-macrophage and erythroid progenitor cells obtained from normal individuals and from patients with chronic myelogenous leukemia. (1983) (8)
Murine myeloid leukemia: I. Pathophysiology and drug sensitivity. (1977) (8)
Cell Cycle Parameters as Biological Predictors of Prognosis in AML: A Review and Update of Cell Cycle Kinetics and Remission Induction/Duration in Acute Leukemia (1992) (8)
The study of acute leukemia cells by means of acridine orange staining and flow cytometry. (1994) (8)
A method for obtaining human bone marrow specimens enriched for myeloblasts and promyelocytes. (1979) (8)
Treatment of Refractory Adult Acute Lymphocytic Leukaemia and Acute Undifferentiated Leukaemia with an Anthracycline Antibiotic and Cytosine Arabinoside (1981) (8)
Chronic myelocytic leukemia: comments on new approaches to therapy. (1982) (8)
Differing effects of inducers of differentiation on the ribonucleotide pool sized of Friend leukemia cells. (1975) (8)
Proliferative characteristics of acute nonlymphocytic leukemia in vivo. (1987) (8)
Cytogenetic study of maturing granulocytes in bone marrow of patients with acute myelogenous leukemia. (1990) (7)
Sustained viability of acute myelogenous leukemia cells in liquid suspension culture correlates with occurrence of differentiation. (1988) (7)
Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes. (2001) (7)
Predictors of response of acute nonlymphocytic leukemia. (1986) (7)
The role of emerging technologies in the diagnosis and staging of neoplastic diseases (1992) (7)
A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents. (1983) (7)
Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia. (1993) (7)
Double labeling of human leukemic cells using 3H-cytarabine and monoclonal antibody against bromodeoxyuridine. (1985) (7)
Murine myeloid leukemia: colony formation in vitro. (1978) (7)
Current problems in the treatment of acute myelocytic leukemia (AML) and some possible solutions. (1992) (7)
The treatment of the myelodysplastic syndromes (1999) (7)
Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia. (1992) (7)
The leukemias. (1994) (6)
Isolation and characterization of the CD34+ hematopoietic progenitor cells from the peripheral blood of patients with chronic myeloid leukemia. (1991) (6)
Cell cycle studies in acute myelogenous leukemia. (1992) (6)
Cell-cycle characteristics - alterable determinants of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid-leukemia. (1993) (6)
Proto-oncogene expression during early myeloid differentiation of normal peripheral blood progenitor cells. (1989) (6)
Effects of cytosine arabinoside on DNA synthesis and the clonogenicity of RF/UN murine myeloid leukemia cells. (1980) (6)
Poor prognosis acute myelogenous leukemia 2--biological and molecular biological characteristics and treatment outcome. (2000) (6)
Acute nonlymphocytic leukemia in a glue sniffer (1985) (6)
In vitro drug sensitivity studies of colony-forming units in culture in chronic myelocytic leukemia: lack of specificity between chronic-phase patients and normal donors. (1983) (6)
In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase. (1983) (6)
Treatment of erythroleukemia with anthracycline antibiotics and cytosine arabinoside (1983) (5)
Differentiation of myeloid cells in liquid culture: 2. Acute myelocytic leukemia cells (1987) (5)
The Premyelodysplastic State and the Secondary Hematologic Disorders (1998) (5)
Clonogenic potential in vitro of proliferative and quiescent leukemic cells. (1980) (5)
Studies of proto-oncogene expression in the chronic and blastic phases of chronic myelogenous leukemia. (1990) (5)
Assessment of cell-cycle effects of cytokines in vivo. (1992) (5)
Drug Uptake and Ribonucleotide Profiles of Blast‐enriched and Blast‐depleted Human Bone Marrow Cell Populations (1977) (5)
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. (1993) (5)
Friend leukemia cells: relationship between differentiation, clonogenicity and malignancy. (1978) (5)
Tyrosine phosphorylation of Shc proteins in normal CD34+ progenitor cells and leukemic cells. (1999) (5)
Effects of partially thiolated polycytidylic acid on the clonogenicity of murine leukemic stem cells. (1979) (5)
Erythropoietin-induced stimulation of heme synthesis by dimethylsulfoxide-treated Friend leukemic cells in vitro. (1974) (5)
Lack of erythroid burst-promoting activity in the media conditioned by eleven human T cell leukemia-lymphoma cell lines. (1982) (5)
Comparison ofin vitro assays for detecting subpopulations of P388 leukemic cells resistant to AraC (1984) (5)
Reduced production of spleen colonies and granulocytes in antibiotic-treated irradiated mice transplanted with syngeneic bone marrow. (1971) (4)
Cytolytic activity of peripheral blood blast cells from patients with acute myeloid leukemia. (1997) (4)
Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside (2004) (4)
Cytokine production by in vitro processed and unprocessed haematopoietic cells. (2000) (4)
Determinants of response and prediction of response to chemotherapy in acute myelogenous leukemia. (1991) (4)
A prospective study of anti‐candida interfering factor in leukemic patients (1972) (4)
Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside (1985) (4)
Carcinoma of unknown primary: natural history and response to therapy. (1978) (4)
Studies of the geographic patterns of c‐myc expression in bone marrow (1991) (4)
CD34 antigen expression of acute myeloid leukemia‐colony forming cells (1992) (4)
Studies of the proliferation and differentiation of immature myeloid cells in vitro: 4: Preculture proto‐oncogene expression and the behaviour of myeloid leukemia cells in vitro (1991) (4)
Cytological and immunological study of 139 patients with acute leukemia (1984) (4)
Protection of normal hematopoietic stem cells from the toxicity of purine base analogs: in vivo application. (1984) (4)
Assessment of apoptosis in relation to proliferation and mutational status of p53 gene in head and neck cancers. (1996) (4)
Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody (1991) (4)
Proto-oncogene expression in differentiating and non-differentiating chronic myelogenous leukaemia cells. (1990) (4)
Blindness in a patient with malignant histiocytosis (1977) (4)
Control of Leukemia Proliferation in vivo in Patients: In vivo Cytokine Production (1998) (4)
Prediction of therapeutic response in acute myelocytic leukemia. (1979) (4)
Studies of the proliferation and differentiation of immature myeloid cells in vitro. I. chronic myelogenous leukemia (1989) (4)
A proposal regarding the reporting of post-remission induction therapies in acute nonlymphocytic leukemia (1986) (4)
Effects of partially thiolated polycytidylic acid and liposomes on in vitro colony-forming cells of leukemic mice. (1982) (3)
Another look at survival curves in chronic myelocytic leukemia (1980) (3)
155 Successful anti-cytokine based approach to treat myelodysplastic syndromes (MDS) (1997) (3)
Cyclin Dl Expression in Squamous Cell Carcinomas of the Head and Neck and in Oral Mucosa in Relation to Proliferation and Apoptosis 1 (2005) (3)
Analysis of the c-myc and N-ras genes in acute myelogenous leukemia cells which manifest the constitutive expression of the c-myc gene. (1993) (3)
In vitro and preliminary in vivo studies of compounds which induce the differentiation of Friend leukemia cells. (1976) (3)
Procurement of Proliferative and Quiescent Acute Leukemia Cells by Centrifugal Elutriation (1978) (3)
Effects of cytosine arabinoside on unseparated bone marrow and peripheral blood cells and on specimens enriched for myeloblasts and promyelocytes. (1980) (3)
Cellular dynamics of leukemias. (1990) (3)
Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia. (1994) (3)
Improved rapid autoradiography with elimination of background (1985) (3)
Studies of Components of Patient Protection Programs: Non-absorbable Antibiotics and Low Bacterial Diets (1970) (3)
Characterization of proliferative and quiescent leukemic cells by flow cytometry. (1981) (3)
Cell cycle characteristics in myeloid leukemias. (1989) (3)
Clonal Growth of Leukaemic Cells In Vitro (1981) (2)
Effects of rGM‐CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA (1991) (2)
Differentiation of myeloid cells in liquid culture. 1. Progenitor cells found in normal perpheral blood (1986) (2)
Comparison of two methods for concentrating CD34+ cells from patients with acute non-lymphocytic leukemia. (1992) (2)
Potential limitations of in vitro clonogenic drug sensitivity assays (2004) (2)
BUDR inhibition of post-DMSO-induced erythroleukaemia cell differentiation in vitro. (1976) (2)
Effectiveness of Interferon-Alfa and Mid-Cycle Chemotherapy Added to an Anthracycline-Based Regimen in the Treatment of Aggressive Non-Hodgkin's Lymphoma (2001) (2)
The effects of 1-3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and cyto- sine arabinoside (arac) on hematopoiesis in the mouse. Abstr. (1969) (2)
Proto-oncogene expression in HL-60 cells exposed to ara-C. (1987) (2)
The effects of exposure to cytosine arabinoside upon the proliferation of leukemia colony forming units in vitro. (1982) (2)
Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients. (1993) (2)
Ultrastructural Changes in Friend Leukemia Cells After Dimethyl Sulfoxide (DMSO), Dimethyl Formamide (DMF), or 5-Bromo-2’-Dioxyuridine (BUdR) Treatment in Vitro (1972) (2)
51. Alteration of Myb and Myc expression in acute myelogenous leukemia cells (AML) in vivo in patients (1992) (2)
Growth of human marrow in plasma clot diffusion chambers. (2009) (2)
Effects of Corynebacterium parvum on murine myeloid leukaemia. (1978) (2)
In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia. (1984) (2)
The role of positron-emission tomography (PET) in the assessment of pathologic response to neoadjuvant chemotherapy with doxorubicin and docetaxel in patients with locally advanced breast cancer (1999) (2)
Effects of N-methylacetamide and splenectomy on RF murine myeloid leukemia. (1979) (2)
Progress toward predictive models for the outcome of treatment for acute nonlymphocytic leukemia. (1987) (2)
Separation of leukemic and nonleukemic subpopulations of spleen cells from mice with myeloid leukemia. (1983) (1)
T-cell depletion of bone marrow does not inhibit in vitro hematopoiesis (1985) (1)
Therapy for patients with acute myelocytic leukemia who enter remission: bone marrow transplantation or chemotherapy? (1982) (1)
Effects of cytosine arabinoside on DNA synthesis and mitotic activity of HL-60 cells (1985) (1)
Prednimustine in acute nonlymphocytic leukemia (1983) (1)
Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias (1985) (1)
Evaluation of in vitro predictive assays for acute myelocytic leukemia (1980) (1)
Lack of relationship between in vitro cell measurements and response to busulfan in chronic myelocytic leukemia (1985) (1)
Translocation (2;7)(p13;q36) in a case of acute nonlymphocytic leukemia evolving from a myelodysplastic syndrome. (1988) (1)
Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B. (1987) (1)
Ara-C incorporation into DNA [letter] (1985) (1)
Selection of optimal remission consolidation therapy for individual patients with acute myelogenous leukemia (2000) (1)
The effects of cytosine arabinoside and GM-CSF in leukemic cells in vitro. (1989) (1)
Establishment of murine myeloid-leukaemia cell line in suspension culture. (1978) (1)
Marrow cytokine transcripts and the secondary hematologic disorders. (1999) (1)
Different Sensitivities of Granulocyte‐Macrophage and Erythroid Progenitor Cells of Normal Human Bone Marrow to S‐Phase‐Specific Agents (1984) (1)
Effects of 13 cis Retinoic Acid(RA) and ainterferon(IFN) on Chronic Myelogenous Leukemia (CML) in vivo in Patients (1995) (1)
Growth of human acute myeloblastic leukemic (AML) cells in vitro (1979) (1)
Prognosis in Head and Neck Cancer (2016) (1)
Regulation of serum cytokines following IL-4 and IL-10 therapy in patients with acute myelogenous leukemia (2000) (1)
Accuracy of immunohistochemistry and flow cytometry in estimating the proportion of leukemic cells in S phase in chronic myeloid leukemia patients. (1996) (1)
121. Effects of retinoic acid, interferon and granulocyte-macrophage colony stimulating factor on human leukemic cells and the hematopoietic microenvironment in vivo (1992) (1)
Bone Marrow Toxicity of Antitumor Agents (1985) (1)
Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias. (2001) (1)
Human T cell leukemia-lymphoma cell lines and granulocyte-macrophage colony stimulating activity. (1980) (1)
167. The proliferative rates of acute myelogenous leukemia cells can be accelerated or slowed in vivo in patients (1992) (0)
Peer Review (2014) (0)
Problems associated with the study of cytokines in patients with leukaemia. (1992) (0)
Sensitization in vitro to murine myeloblastic leukemia cells by xenogeneic immune RNA. (1979) (0)
Recent advances in hematology as related to diseases of the colon and rectum. (1972) (0)
Murine myeloid leukemia as a model system for aml in man. Abstr. (1976) (0)
Novel Therapies with Biologic Response Modifiers to Reverse Extremely High Apoptosis in Myelodysplastic Syndromes (MDS) (1995) (0)
Abnormalities in the expression of the P15 tumor suppressor gene and in cytokine production during the development of secondary hematologic disorders (2000) (0)
Effect of suppression of erythropoiesis on colony-forming units of mice. Abstr. (1969) (0)
23. Cytokines/stromal cells in hematopoietic microenvironment influence proliferation/differentiation of acute myeloid leukemia cells (1992) (0)
Abstracts from Twenty-Fourth Annual Meeting (2007) (0)
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia (2004) (0)
Effects of cornynebacterium parvum (c. Parvum)r@@@ on mu myeloid leukemia. Abstr. (1977) (0)
Neoplastic Progression of the Myeloid Leukemias (1989) (0)
TREATMENT CHOICES FOR PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA IN REMISSION: CHEMOTHERAPY AND BONE MARROW TRANSPLANTATION (1985) (0)
A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. (2003) (0)
Detection of K-ras mutation in a patient with multiple tumors. (1996) (0)
96 Cytokine production in vivo in mds and AML patients (1997) (0)
Migration inhibition of sensitized mouse spleen cells by cell-associated transplantation antigens: effect of method of antigen presentation. (1978) (0)
Separation of leukemic myeloblasts and splenic lymphocytes based upon differences in light scatter profile. (1979) (0)
Effects of cytosine arabinoside on rf/un murine myeloid leukemia cells. Abstr. (1979) (0)
Chemotherapy in AML. (1984) (0)
OPEN FORUM A paradigm shift in myelodysplastic syndromes (2019) (0)
Anti-candidal agglutinating antibody. (1969) (0)
Clonogenicity and malignancy. (1978) (0)
162 Potential for use of amifostine in the treatment of poor prognosis acute myelogenous leukemia (1997) (0)
Myc expression in myeloid cells measured by northern blot analysis and flow cytometry (1990) (0)
Differentiation, clonogenicity and malignancy of friend leukemia cells (flc). Abstr. (1977) (0)
92 Stem cell defect and the genesis of cytopenias in myelodysplastic syndromes (MDS) and their correction by amifostine (1997) (0)
Kinetic Resistance, Regrowth Resistance, and Multidrug Resistance in the Treatment of Acute Myelogenous Leukemia (AML) (1996) (0)
Acquisition of selected subpopulations of leukemic cells for study. (1980) (0)
Ara-C incorporation into DNA. (1985) (0)
Genetic mechanisms in chronic myelogenous leukemia. (1990) (0)
GENERAL DISCUSSION (1978) (0)
Rational approaches to the treatment of leukemia. (1981) (0)
Studies on the transfer of immunity to rfm/un murine myeloid @@le (1977) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Harvey D. Preisler?

Harvey D. Preisler is affiliated with the following schools:

Columbia University